Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.

被引：47
|
作者：
Overman, Michael J.
Kopetz, Scott
McDermott, Raymond S.
Leach, Joseph
Lonardi, Sara
Lenz, Heinz-Josef
Morse, Michael A.
Desai, Jayesh
Hill, Andrew
Axelson, Michael D.
Moss, Rebecca Anne
Lin, Chen-Sheng
Goldberg, Monica
Andre, Thierry
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] St Vincents Univ Hosp, Dublin, Ireland
[3] Allina Hlth Syst, Minneapolis, MN USA
[4] Ist Oncol Veneto IOV IRCSS, Padua, Italy
[5] Univ Southern Calif, Los Angeles, CA USA
[6] Duke Univ Off Res Adm, Durham, NC USA
[7] Royal Melbourne Hosp, Melbourne, Australia
[8] Tasman Oncol Res Pty Ltd, Southport, Qld, Australia
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Hop St Antoine, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.3501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3501
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Nivolumab ± ipilimumab treatment (Tx) efficacy, safety, and biomarkers in patients (Pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): results from the CheckMate-142 study
    Overman, M. J.
    Kopetz, S.
    Lonardi, S.
    McDermott, R.
    Leone, F.
    Leach, J.
    Lenz, H-J.
    Hendlisz, A.
    Morse, M.
    Garcia-Alfonso, P.
    Desai, J.
    Hill, A.
    Moss, R. A.
    Goldberg, M. V.
    Lin, C-S.
    Tang, H.
    Andre, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [3] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [4] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
    Andre, Thierry
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Morse, Michael
    McDermott, Raymond S.
    Hill, Andrew Graham
    Hendlisz, Alain
    Lenz, Heinz-Josef
    Leach, Joseph W.
    Moss, Rebecca Anne
    Cao, Z. Alexander
    Ledeine, Jean-Marie
    Chan, Emily
    Kopetz, Scott
    Michael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [6] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Results from the Phase-II-Study CheckMate-142 Nivolumab in Combination with Ipilimumab shows Activity in pretreated Patients with metastatic Colorectal Carcinoma with MMR Defect or MSI-H
    不详
    VISCERAL MEDICINE, 2017, 33 (04) : 308 - 308
  • [8] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [9] Nivolumab in patients with DNA mismatch repairdeficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.
    Overman, Michael J.
    Bergamo, Francesca
    McDermott, Raymond S.
    Aglietta, Massimo
    Chen, Franklin
    Gelsomino, Fabio
    Wong, Mark
    Morse, Michael
    Van Cutsem, Eric
    Hendlisz, Alain
    Neyns, Bart
    Moss, Rebecca Anne
    Zhao, Huanyu
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Exploratory analysis of Janus kinase 1 (JAK1) loss-of-function (LoF) mutations in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab plus ipilimumab in CheckMate-142
    Kopetz, Scott
    Andre, Theirry
    Overman, Michael J.
    Zagonel, Vittorina
    Lonardi, Sara
    Aglietta, Massimo
    Gelsomino, Fabio
    McDermott, Ray
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Garcia Alfonso, Pilar
    Lenz, Heinz-Josef
    Walsh, Alice
    Moss, Rebecca A.
    Greenawalt, Danielle
    Cao, Z. Alexander
    CANCER RESEARCH, 2018, 78 (13)
12345